University of Cambridge

A Cambridge-led clinical trial found that combining metformin (diabetes drug) with clemastine (antihistamine) helped maintain nerve function in 70 people with relapsing multiple sclerosis over six months.

Nxera Pharma and Cancer Research UK have dosed the first patient in a Phase 2a trial of HTL0039732, an oral EP4 antagonist immunotherapy for advanced solid tumors.

University of Cambridge researchers have engineered artificial cartilage that automatically releases anti-inflammatory drugs in response to the acidic conditions present during arthritis flare-ups.

Cambridge-based Cyted Health raised €37.5 million in Series B funding led by EQT Life Sciences, Advent Life Sciences, and British Business Bank to accelerate US commercial expansion of its esophageal cancer diagnostics platform.

Cyted Health raised $44 million in Series B funding led by EQT Life Sciences to accelerate commercial expansion of its gastrointestinal molecular diagnostics platform in the United States.

GSK received FDA Orphan Drug Designation for its investigational treatment of autosomal dominant polycystic kidney disease (ADPKD), a rare genetic disorder affecting approximately 600,000 people in the U.S.

Cumulus Neuroscience's CNS-101 study demonstrated that at-home digital cognitive endpoints showed greater separation with Alzheimer's pathology (pTau217) than the benchmark ADAS-Cog 13 scale over the study time-course.

Princess Anne officially opened Insmed's new 17,000 square foot research facility in Cambridge, UK, dedicated to synthetic rescue technology for rare diseases.

The Cell and Gene Therapy Catapult made its first investment through the Cross-Catapult Investment Pilot in Spliceor, a Cambridge University spinout developing trans-splicing gene therapy for liver cancer.

The National Institute for Health and Care Research is piloting a 'Just in Time' scheme that could reduce clinical trial setup time from months to days, potentially improving patient access to trials closer to home.